Format

Send to

Choose Destination
Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331.

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).

Author information

1
Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
2
Oncology Department, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Italy.
3
Oncology Department, Ospedale Fatebenefratelli e Oftalmico, Milan, Italy.
4
Medical Oncology Department, Policlinico Umberto I Rome, Italy.
5
Oncology Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.
6
Medical Oncology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy.
7
Medical Oncology Department, Ospedale Belcolle, Viterbo, Italy.
8
Medical Oncology Department, San Giovanni e Addolorata Hospital, Rome, Italy.
9
Oncology Department, Azienda Ospedaliera Desio e Vimercate, Vimercate, Italy.
10
San Carlo Borromeo Hospital, Milano, Italy.
11
Valtellina e Valchiavenna Hospital, Sondrio, Italy.
12
Valtellina e Valchiavenna Hospital, Sondalo, Italy.
13
San Pietro Hospital, Roma, Italy.
14
Legnano Hospital, Legnano, Italy.
15
Azienda Ospedaliera Universitaria, Sassari, Italy.

Abstract

MicroRNAs were described to target mRNA and regulate the transcription of genes involved in processes de-regulated in tumorigenesis, such as proliferation, differentiation and survival. In particular, the miRNA let-7 has been suggested to regulate the expression of the KRAS gene, a common mutated gene in non-small cell lung cancer (NSCLC), through a let-7 complementary site (LCS) in 3'UTR of KRAS mRNA. We have reported the analysis performed on the role of the polymorphism located in the KRAS-LCS (rs61764370) which is involved in the disruption of the let-7 complementary site in NSCLC patients enrolled within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line treatment. In our cohort of patients, KRAS-LCS6 polymorphism did not have any impact on both overall survival (OS) and progression free survival (PFS) and was not associated with any patient's baseline characteristics included in the study. Overall, patients had a better prognosis when treated with docetaxel instead of erlotinib for both OS and PFS. Considering KRAS-LCS6 status, the TG/GG patients had a benefit from docetaxel treatment (HR(docetaxel vs erlotinib) = 0.35, 95% CI 0.15-0.79, p = 0.011) compared with the TT patients (HR(docetaxel vs erlotinib) = 0.72, 95% CI 0.52-1.01, p = 0.056) in terms of PFS.

PMID:
26573509
PMCID:
PMC4648064
DOI:
10.1038/srep16331
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center